Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imagify gets “complete response”

Executive Summary

An FDA "complete response" letter for Acusphere's Imagify suggests that additional clinical work will be required to support its proposed use as a screening tool to stratify patients for referral to coronary arteriography, the firm announces March 11. The company says the letter is largely consistent with the feedback it received from an FDA advisory committee in December; the panel voted 16-1 with one abstention against Imagify approval due to evolving trial design standards, miscommunication with the FDA review division, inconsistent efficacy, safety signals and unconvincing diagnostic value (1"The Pink Sheet," Dec. 15, 2008, p. 17). Acusphere submitted a narrower claim for the imaging agent in February with a potentially improved risk-benefit ratio, and is in the process of scheduling a meeting with FDA to discuss alternatives

You may also be interested in...



Acusphere Future Up In Air After Imagify Fails Before Advisory Panel

Evolving trial design standards and miscommunication with the review division tripped up Acusphere's effort to bring Imagify to market, signaling to competitors in the space that FDA is raising the bar on contrast imaging agents

Health And Wellness Trademark Review 19 January, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Europe's CBD Market In 2020: Narcotic Vs Novel Food

INFOGRAPHIC: An interactive timeline of selected HBW Insight coverage of the growing European CBD dietary supplements market in 2020. The timeline covers the main events of a rollercoaster 12 months, including the European Commission’s indecision on whether to classify CBD as narcotic or novel food and how the path forward became clear in the UK.

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel